Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an announcement.
On January 16, 2025, XORTX Therapeutics Inc. announced a change in its auditing firm. Smythe LLP resigned as the company’s auditor, and Davidson & Company LLP was appointed as the successor. The transition was approved by XORTX’s Audit Committee and Board of Directors, and there were no disagreements or issues reported with the former auditor. This change is part of the company’s ongoing efforts to ensure robust financial oversight and transparency in its operations.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a pharmaceutical company based in Calgary, Alberta, focusing on therapies for rare diseases. It specializes in developing treatments for progressive kidney disease and Type 2 diabetic nephropathy to address unmet medical needs.
YTD Price Performance: -15.66%
Average Trading Volume: 3,625
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$4.87M
For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.
